

In addition to the recent investigation by Hernan et al (an *American* study performed on a *British* database), the following bibliography, although not exhaustive, demonstrates that the issue of hepatitis B vaccine unusual toxicity is by no way a new *French paradox*..

1. Aaron-Maor A, Shoenfeld Y. The good, the bad and the ugly of vaccination. *Israel Medical Association Journal*: IMAJ 2000; 2(3):225-7.
2. Adachi Y, Yasui H, Yuasa H, Ishi Y, Imai K, Kato Y. Hepatitis b virus-associated aplastic anemia followed by myelodysplastic syndrome. *American Journal of Medicine*. 112(4):330-332, 2002 Mar.
3. Aherne P, Collins M. Psoriatic arthropathy [letter]. *Irish Medical Journal* 1995; 88(2):72.
4. Ajithkumar K, Anand U, Pulimood S *et al*. Vaccine-induced necrobiotic granuloma. *Clinical & Experimental Dermatology* 1998; 23(5):222-4.
5. Al-Khenaizan S. Lichen planus occurring after hepatitis B vaccination: A new case. *Journal of the American Academy of Dermatology* 2001; 45(4):614-5.
6. Albitar S, Bourgeon B, Genin R *et al*. Bilateral retrobulbar optic neuritis with hepatitis B vaccination. *Neurology Dialysis Transplantation* 1997; 12:2169-70.
7. Allen MB, Cockwell P, Page RL. Pulmonary and cutaneous vasculitis following hepatitis B vaccination. *Thorax* 1993; 48:580-1.
8. Ambrosch F, Andre FE, Delem A *et al*. Simultaneous vaccination against hepatitis A and B: results of a controlled study. *Vaccine* 1992; 10 Suppl 1:S142-5.
9. Ambrosch F, Wiedermann G, Andre FE *et al*. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. *Journal of Medical Virology* 1994; 44(4):452-6.
10. Andiran N, Senturk GB, Bukulmez G. Combined vaccination by measles and hepatitis B vaccines: A new cause of Gianotti-Crosti syndrome. *Dermatology* 2002; 204(1):75-6.
11. Anonymous. Adverse events following the administration of hepatitis B vaccines. *CCDR* 1992; 18-7:49-56.
12. Anonymous. Expanded programme on immunization (EPI). Lack of evidence that hepatitis B vaccine causes multiple sclerosis. *Weekly Epidemiological Record* 1997; 72(21):149-52.
13. Anonymous. National advisory committee on immunization (NACI). Statement on hepatitis B vaccine [published erratum appears in *Can Commun Dis Rep* 1993 Aug 30;19(16):135]. *Canada Communicable Disease Report* 1993; 19(14):104-15.
14. Anonymous. No link between hepatitis B vaccine and neurologic disorders. *Hospital Formulary*. 37(7):336-337, 2002 Jul.
15. Anonymous. No scientific justification to suspend hepatitis B immunization [news]. *Public Health* 1998; 113(6):487.
16. Anonymous. Report of the Hepatitis B Working Group. *Canada Communicable Disease Report* 1994; 20(13):105-12.
17. Anonymous. Report of the working group on the possible relationship between hepatitis B vaccination and the chronic fatigue syndrome. *CMAJ* 1993; 149(3):314-9.
18. Anonymous. Report of the working group on the possible relationship between hepatitis B

- vaccination and the chronic fatigue syndrome. Canada Communicable Disease Report 1993; 19(4):25-8.
19. Anonymous. Statement on hepatitis B vaccine. National Advisory Committee on Immunization. CMAJ 1993; 149(10):1465-80.
 20. Anonymous. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP) [published erratum appears in MMWR Morb Mortal Wkly Rep 1997 Mar 14;46(10):227]. MMWR - Morbidity & Mortality Weekly Report 1996; 45(RR-12):1-35.
 21. Aristegui J, Muniz J, Perez Legorburu A *et al.* Newborn universal immunisation against hepatitis B: immunogenicity and reactogenicity of simultaneous administration of diphtheria/tetanus/pertussis (DTP) and oral polio vaccines with hepatitis B vaccine at 0, 2 and 6 months of age. Vaccine 1995; 13(11):973-7.
 22. Aron E. Pharmacovigilance of hepatitis B vaccines - Discussion [French]. Bulletin De l'Academie Nationale De Medecine 2003; 187(8):1498.
 23. Aron-Maor A, Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas [review]. Lupus 2001; 10(3):237-40.
 24. Arya SC. Ophthalmic complications of vaccines against hepatitis B virus [letter]. International Ophthalmology 1997; 21(3):177-8.
 25. Ascherio A, Zhang SM, Hernan MA *et al.* Hepatitis B vaccination and the risk of multiple sclerosis. New England Journal of Medicine 2001; 344(5):327-32.
 26. Ascherio A, Zhang SM, Walker AM. Vaccinations and multiple sclerosis - Reply. New England Journal of Medicine 2001; 344(23):1795.
 27. Aspinall S, Kocks DJ. Immunogenicity of a low-cost hepatitis B vaccine in the South African Expanded Programme on Immunisation. South African Medical Journal 1998; 88(1):36-9.
 28. Aubin F, Angonin R, Humbert P *et al.* Lichen planus following hepatitis B vaccination. Arch Dermatol 1994; 130:1329-30.
 29. Aubin F, Humbert P. Complications dermatologiques liées à la vaccination anti-hépatite B. Revue Française D'Allergologie Et D'Immunologie Clinique 1994; 34:495-7.
 30. Authier FJ, Cherin P, Creange A *et al.* Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001; 124(Part 5):974-83.
 31. Authier FJ, Sauvat S, Champey J, Drogou I, Coquet M, Gherardi RK. Chronic fatigue syndrome in patients with macrophagic myofasciitis. Arthritis & Rheumatism 2003; 48(2):569-70.
 32. Averhoff F, Linton L, Peddecord KM, Edwards C, Wang W, Fishbein D. A middle school immunization law rapidly and substantially increases immunization coverage among adolescents. American Journal of Public Health 2004; 94(6):978-84.
 33. Baglivo E, Safran AB, Borruat FX. Multiple evanescent white dot syndrome after hepatitis B vaccine. American Journal of Ophthalmology 1996; 122(3):431-2.
 34. Ball R, Halsey N, Braun NM *et al.* Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the Vaccine Adverse Event Reporting System. Journal of Clinical Epidemiology 2002; 55(8):819-24.

35. Ballesteros-Trujillo A, Vargas-Origel A, Alvarez-Munoz T, Aldana-Valenzuela C. Response to hepatitis B vaccine in preterm infants: Four-dose schedule. *American Journal of Perinatology* 2001; 18(7):379-85.
36. Ballinger AB, Clark ML. Severe acute hepatitis B infection after vaccination [letter] [see comments]. *Lancet* 1994; 344(8932):1292.
37. Bantz PM, Peiser C, Groneberg DA. Peripheral neurological symptoms after hepatitis B virus vaccination. *QJM* 2003; 96(8):611.
38. Barbaud A, Trechot P, Reichert-Penetrat S, Weber M, Schmutz JL. Allergic mechanisms and urticaria/angioedema after hepatitis B immunization [letter]. *British Journal of Dermatology* 1998; 139(5):925-6.
39. Bardazzi F, Landi C, Orlandi C, Neri I, Varotti C. Graham Little-Piccardi-Lasseur syndrome following HBV vaccination [letter]. *Acta Dermato-Venereologica* 1999; 79(1):93.
40. Bardenheier B, Yusuf H, Schwartz B, Gust D, Barker L, Rodewald L. Are parental vaccine safety concerns associated with receipt of measles-mumps-rubella, diphtheria and tetanus toxoids with acellular pertussis, or hepatitis B vaccines by children? *Archives of Pediatrics & Adolescent Medicine* 2004; 158(6):569-75.
41. Bartlett MJ, Burgess MA, McIntyre PB, Heath TC. Parent and general practitioner preferences for infant immunisation. Reactogenicity or multiple injections?. *Australian Family Physician* 1999; 28 suppl 1:S22-7.
42. Bassily S, Kotkat A, Gray G *et al*. Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. *American Journal of Tropical Medicine & Hygiene* 1995; 53(4):419-22.
43. Battafarano DF, Battafarano NJ, Larsen L *et al*. Antigen-specific antibody responses in lupus patients following immunization. *Arthritis Rheum* 1998; 41:1828-34.
44. Battafarano DF, Enzanauer RJ. Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy: comment on the article by Battafarano et al -Reply. *Arthritis Rheum* 1999; 42:1308.
45. Battaglia A, Valiani R. Description of a case of seizures following anti-hepatitis B immunization. *Rass Med Sper* 1992; 39:119-22.
46. Baumgarten R. [Viral hepatitis: preventable illnesses]. [Review] [6 refs] [German]. *Zeitschrift Fur Arztliche Fortbildung Und Qualitatssicherung* 1998; 92(10):677-80.
47. Begaud B, Alperovitch A. Vaccinations and multiple sclerosis. *New England Journal of Medicine* 2001; 344(23):1793.
48. Bell A. Universal hepatitis B immunization: the British Columbia experience. *Vaccine* 1995; 13 Suppl 1:S77-81.
49. Bennett RG, Powers DC, Remsburg RE, Scheve A, Clements ML. Hepatitis B virus vaccination for older adults. *Journal of the American Geriatrics Society* 1996; 44(6):699-703.
50. Bensaid J, Denis F. Benign acute pericarditis after vaccination against hepatitis B. *Presse Med* 1993; 22:269.

51. Bentsi-Enchill A. Adverse events following the administration of hepatitis B vaccines. *Canada Communicable Disease Report* 1992; 18(7):49-53.
52. Beretta L, Vanoli M, Caronni M, Scorza R. Churg-Strauss vasculitis with brain involvement following hepatitis B vaccination. *Clinical & Experimental Rheumatology* 2001; 19(6):757.
53. Berkman N. [A case of segmentary unilateral occlusion of the central retinal vein following hepatitis B vaccination (letter)]. [French]. *Presse Medicale* 1997; 26(14):670.
54. Berkman N, Benzarti T, Dhaoui R, Mouly P. [Bilateral neuro-papillitis after hepatitis B vaccination (letter)]. [French]. *Presse Medicale* 1996; 25(28):1301.
55. Bernard S. Association between thimerosal-containing vaccine and autism. *Jama: Journal of the American Medical Association* 2004; 291(2):180.
56. Bernier R, Midthun K. Getting the science right and doing the right science in vaccine safety. *American Journal of Public Health* 2004; 94(6):914-7.
57. Beytout J. Controversy surrounding the vaccination against hepatitis B [French]. *MEDECINE ET MALADIES INFECTIEUSES* 2003; 33(1):1-2.
58. Biacabe B, Erminy M, Bonfils P. A case report of fluctuant sensorineural hearing loss after hepatitis B vaccination. *Auris, Nasus, Larynx* 1997; 24(4):357-60.
59. Biasi D, Carletto A, Caramaschi P *et al.* Rheumatological manifestations following hepatitis B vaccination. A report of 2 clinical cases. *Recenti Prog Med* 1994; 85:438-40.
60. Biasi D, De Sandre G, Bambara LM *et al.* A new case of reactive arthritis after hepatitis B vaccination. *Clin Exp Rheumatol* 1993; 11:215-20.
61. Birley HD, Arya OP. Hepatitis B immunisation and reactive arthritis [letter; comment]. *BMJ* 1994; 309(6967):1514.
62. Birmingham K. Public pressure alters French vaccination policy [news]. *Nature Medicine* 1998; 4(11):1217.
63. Biron P, Montpetit P, Infante-Rivard C *et al.* Myasthenia gravis after general anesthesia and hepatitis B vaccine. *Archives of Internal Medicine* 1988; 148:2685.
64. Biroscak BJ, Fiore AE, Fasano N, Fineis P, Collins MP, Stoltman G. Impact of the thimerosal controversy on hepatitis B vaccine coverage of infants born to women of unknown hepatitis B surface antigen status in Michigan. *Pediatrics* 2003; 111(6):E645-E649.
65. Blancher G. Vaccination against hepatitis [French]. *Bulletin De l'Academie Nationale De Medecine* 2002; 186(9):1659-60.
66. Blum HE, Marcellin P. EASL International Consensus Conference on Hepatitis B - 13-14 September, 2002, - Geneva, Switzerland Consensus Statement (Long version) - Foreword. *Journal of Hepatology* 2003; 39(Suppl 1):S1-S2.
67. Bock HL, Kruppenbacher J, Sanger R, Hobel W, Clemens R, Jilg W. Immunogenicity of a recombinant hepatitis B vaccine in adults. *Archives of Internal Medicine* 1996; 156(19):2226-31.
68. Bohlke K, Davis RL, Marcy SM *et al.* Risk of anaphylaxis after vaccination of children and adolescents. *Pediatrics* 2003; 112(4):815-20.

69. Bonanni P, Crovari P. Success stories in the implementation of universal hepatitis B vaccination: an update on Italy [published erratum appears in *Vaccine* 1999 Apr 9;17(15-16):I-II]. [Review] [13 refs]. *Vaccine* 1998; 16 Suppl:S38-42.
70. Bonfils P, Biacabe B, Potard G, Aidan D. [Fluctuant perception hearing loss after hepatitis B vaccine]. [French]. *Annales d Oto-Laryngologie Et De Chirurgie Cervico-Faciale* 1996; 113(6):359-61.
71. Bourgeois AM, Dore MX, Croue A, Leclech C, Verret JL. Cutaneous polyarteritis nodosa following hepatitis B vaccination. [French]. *ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE* 2003; 130(2 Part 1):205-7.
72. Bourges JL, Pisella PJ, Laurens C, Limon S. [Multifocal placoid epitheliopathy and anti-hepatitis B vaccination]. [French]. *Journal Francais d Ophthalmologie* 1998; 21(9):696-700.
73. Bouroz-Joly J, Hachulla E, Vermersch P, Pruvo JP, Hatron PY, Devulder B. [Between the infection and the vaccine, one must choose]. [French]. *Revue De Medecine Interne* 1998; 19 Suppl 2:286s-9s.
74. Boxall E, Plester G, Webber S. Vaccine hypersensitivity or coincidental virus infection. *Vaccine* 1989; 7:77.
75. Bracci M, Zoppini A. Polyarthritits associated with hepatitis B vaccination. *Br J Rheumatol* 1997; 36:300-1.
76. Bravo L, Carlos J, Gatchalian S *et al*. The new DTPw-HBV-Hib combination vaccine can be used at the who schedule with a monovalent dose of hepatitis B vaccine at birth. *Southeast Asian Journal of Tropical Medicine & Public Health* 1998; 29(4):772-8.
77. Brezin AP, Lautier-Frau M, Hamedani M *et al*. Visual loss and eosinophilia after recombinant hepatitis B vaccine. *Lancet* 1993; 342:563-4.
78. Brezin AP, Massin-Korobelnik P, Boudin M *et al*. Acute posterior multifocal placoid pigment epitheliopath after hepatitis B vaccine. *Arch Ophthalmol* 1995; 113:297-300.
79. Brightman G, Scadding G, Dumbreck L *et al*. Yeast-derived hepatitis B vaccine and yeast sensitivity. *Lancet* 1989; i:903.
80. Bryan JP, Craig PG, Reyes L *et al*. Randomized comparison of 5 and 10 microgram doses of two recombinant hepatitis B vaccines. *Vaccine* 1995; 13(11):978-82.
81. Bui-Quang D, Thomas E, Riols M *et al*. [Cutaneous vasculitis after hepatitis B vaccination with recombinant vaccine in a renal transplant patient]. [French]. *Presse Medicale* 1998; 27(26):1321-3.
82. Bulkow LR, McMahon BJ, Wainwright RB, Parkinson AJ, Wainwright KY, House J. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine formulation in healthy adults. *Arctic Medical Research* 1993; 52(3):118-26.
83. Buttinelli C, Salvetti M, Ristori G. Vaccinations and multiple sclerosis. *New England Journal of Medicine* 2001; 344(23):1794.
84. Cabezas C, Echevarria C, Gomez G, Gotuzzo E. [Pilot program of immunization against viral hepatitis B, integrated in the extended immunization program in Abancay (peru)]. [Spanish]. *Revista De Gastroenterologia Del Peru* 1995; 15(3):215-22.

85. Caillard J, Bastard C, Czernichow P *et al.* Effets secondaires de la vaccination contre l'hépatite à virus B. Etude sur 1047 sujets au CHRU de Rouen. *LARC Médical* 1985; 5:129-32.
86. Cales P. Anti-hepatitis B vaccine: a step towards resolving a conflictual situation? [French]. *Gastroenterologie Clinique Et Biologique* 2003; 27(10):865-7.
87. Cales P. Hepatitis B vaccination and serious side-effects: sequence is not consequence [French]. *Gastroenterologie Clinique Et Biologique* 2001; 25(10):859-62.
88. Campins Marti M, Moraga Llop FA. [Hepatitis B vaccine and multiple sclerosis (editorial)]. [Review] [15 refs] [Spanish]. *Anales Espanoles De Pediatria* 1998; 49(6):555-7.
89. Canada Communicable Disease Report. Adverse events after hepatitis B vaccination. *Canadian Medical Association Journal* 1992; 147:1023-6.
90. Carmeli Y, De-Medina T. Serious hepatitis B vaccine adverse reactions, are they immune-mediated? [letter]. *Vaccine* 1993; 11(13):1358-9.
91. Carmeli Y, Oren R. Hepatitis B vaccine side-effects. *Lancet* 1993; 341:250-1.
92. Casals JL, Vazquez MA. [Arthritis induced by antihepatitis B vaccine (letter)]. [Spanish]. *Anales De Medicina Interna* 1999; 16(11):601-2.
93. Castelain P, Castelain M, Vervloet D *et al.* Sensitization to aluminium by aluminium-precipitated dms and pollen extracts. *Contact Dermatitis* 1988; 19:58-60.
94. Castresana-Isla CJ, Herrera-Martinez G, Vega-Molina J. Erythema nodosum and Takayasu arteritis after immunization with plasma derived hepatitis B vaccine. *J Rheumatol* 1993; 20:1417-8.
95. Catania G, Di Ciommo V, Concato C. Vaccination against hepatitis B virus in children and adolescents in a pediatric hospital. *Recenti Progressi in Medicina* 1996; 87(6):271-4.
96. Cathebras P, Cartry O, Lafage-Proust MH *et al.* Arthritis, hypercalcemia, and lytic bone lesions after hepatitis B vaccination. *J Rheumatol* 1996; 23:558-60.
97. CDC. Trends: safety of hepatitis B virus vaccine. *JAMA* 1983; 249:1812.
98. CDWR. Alleged link between hepatitis B vaccine and chronic fatigue syndrome. *Can Dis Wkly Rep* 1991; 17:215-6.
99. Challapalli M, Slosar M, Vasa R, Cunningham DG. Brief surface antigenemia in newborn infants vaccinated with hepatitis B vaccine. *Pediatric Infectious Disease Journal* 1993; 12(10):878-9.
100. Chan CY, Lee SD, Lo KJ. Legend of hepatitis B vaccination: The Taiwan experience [Review]. *Journal of Gastroenterology & Hepatology* 2004; 19(2):121-6.
101. Chau KF, Cheng YL, Tsang DNC *et al.* Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: A comparison with the intramuscular vaccination. *American Journal of Kidney Diseases* 2004; 43(5):910-7.
102. Chave T, Neal C, Camp R. Henoch-Schonlein purpura following hepatitis B vaccination. *Journal of Dermatological Treatment* 2003; 14:179-81.
103. Chen CC, Chang MH, Lee HC, Twu SJ, Safary A. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule. *Chung-Hua Min*

- Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih 1999; 40(3):157-60.
104. Chen RT, DeStefano F, Pless R, Mootrey G, Kramarz P, Hibbs B. Challenges and controversies in immunization safety. *Infectious Disease Clinics of North America* 2001; 15(1):21-+.
 105. Cherin P, Herson S. Les myopathies inflammatoires. *Revue De Rhumatisme (Suppl Pédagogique)* 1999; 66:159-71.
 106. Cherin P, Laforet P, Gherardi RK *et al.* La myofascite à macrophages: description, hypothèses étiopathogéniques. *Revue De Médecine Interne* 1999; 26:483-9.
 107. Chuh AAT, Chan HHL, Chiu SSS, Ng HY, Peiris JSM. A prospective case control study of the association of Gianotti-Crosti syndrome with human herpesvirus 6 and human herpesvirus 7 infections. *Pediatric Dermatology* 2002; 19(6):492-7.
 108. Ciacco M, Rebora A. Lichen planus following HBV vaccination, a coincidence? *Br J Dermatol* 1990; 122:424.
 109. Classen JB. Childhood immunisation and diabetes mellitus [letter] [see comments]. *New Zealand Medical Journal* 1996; 109(1022):195.
 110. Classen JB. The diabetes epidemic and the hepatitis B vaccines [letter]. *New Zealand Medical Journal* 1996; 109(1030):366.
 111. Cockwell P, Allen M, Page R. Vasculitis related to hepatitis B vaccine. *Br Med J* 1990; 301:1281.
 112. Cohen A, Shoenfeld Y. Vaccine-induced autoimmunity. *J Autoimmun* 1996; 9:699-703.
 113. Colichon A, Vildosola H, Sjogren M, Cantella R, Safary A. [The serological response to a recombinant DNA vaccine in the native residents of 2 hyperendemic hepatitis B areas in the Peruvian Amazonia]. [Spanish]. *Revista De Gastroenterologia Del Peru* 1993; 13(2):78-84.
 114. Confavreux C, Suissa S, Saddier P. Vaccinations and multiple sclerosis. *New England Journal of Medicine* 2001; 344(23):1795-6.
 115. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. *New England Journal of Medicine* 2001; 344(5):319-26.
 116. Confavreux C. Vaccination et sclérose en plaques: où en est-on. *Revue Du Praticien* 2002; 52(2093-2095).
 117. Conry RM, Curiel DT, Strong TV *et al.* Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. *Clinical Cancer Research* 2002; 8(9):2782-7.
 118. Cooper GS, Dooley MA, Treadwell EL, Clair EWS, Gilkeson GS. Risk factors for development of systemic lupus erythematosus: Allergies, infections, and family history. *Journal of Clinical Epidemiology* 2002; 55(10):982-9.
 119. Cosnes A, Fléchet ML, Revuz J. Inflammatory nodular reactions after hepatitis B vaccination due to aluminium sensitization. *Contact Dermatitis* 1990; 23:65-7.
 120. Coursaget P, Leboulleux D, Soumare M *et al.* Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. *Journal of Hepatology* 1994; 21(2):250-4.
 121. Cox N, Moss C. Cutaneous reactions to aluminium in vaccines: an avoidable problem. *Lancet*

- 1988; ii:43.
122. Creange A, Temam G, Lefaucheur JP. Lumbosacral acute demyelinating polyneuropathy following hepatitis B vaccination. *Autoimmunity* 1999; 30(3):143-6.
 123. Criel C. [Controversy about a vaccine]. [French]. *Soins - Psychiatrie* 1998; (197):suppl IV.
 124. Csepregi A, Nemesanszky E, Rojkovich B, Poor G. Rheumatoid arthritis and hepatitis B virus: Evaluating the pathogenic link. *Journal of Rheumatology* 2001; 28(3):474-7.
 125. Czeschinski PA, Binding N, Witting U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. *Vaccine* 2000; 18(11-12):1074-80.
 126. D'Argenio P, Citarella A, Intorcchia M, Aversano G. An outbreak of vaccination panic [letter]. *Vaccine* 1996; 14(13):1289-90.
 127. Da Silva L, Rogers M. Hepatitis B vaccine: urticarial reaction. *Medical Journal of Australia* 1985; 143:323-4.
 128. Daoud MS, Dicken CH. Anetoderma after hepatitis B immunization in two siblings. *Journal of the American Academy of Dermatology* 1997; 36(5 Pt 1):779-80.
 129. Davanipour Z, Stewart C, McGann D. Hepatitis B vaccination and asymmetric tinnitus and hearing loss. *Clinical Research* 1994; 42:341A.
 130. de Franchis R, Hadengue A, Lau G *et al.* EASL International Consensus Conference on Hepatitis B - 13-14 September, 2002 Geneva, Switzerland Consensus Statement (Long version). *Journal of Hepatology* 2003; 39(Suppl 1):S3-S25.
 131. Degos F. The benefit-risk politics of vaccination against hepatitis B virus [comment]. [Review] [17 refs]. *Italian Journal of Gastroenterology & Hepatology* 1999; 31(5):392-4.
 132. Deisenhammer F, Pohl P, Bosch S, Schmidauer C. Acute cerebellar ataxia after immunisation with recombinant hepatitis B vaccine. *Acta Neurologica Scandinavica* 1994; 89(6):462-3.
 133. Deisenhammer F, Pohl P, Grubwieser G. Childhood immunizations [letter; comment]. *New England Journal of Medicine* 1993; 328(19):1421; discussion 1421-2.
 134. del Canho R, Grosheide PM, Voogd M, Huisman WM, Heijtkink RA, Schalm SW. Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. *Journal of Medical Virology* 1993; 41(1):30-4.
 135. Delage G, Salit I, Pennie R, Alary M, Duval B, Ward B. [The possible relation between hepatitis B vaccination and chronic fatigue syndrome]. [French]. *Union Medicale Du Canada* 1993; 122(4):278-9.
 136. Delbrel X, Fach J, Neau D *et al.* Lupus flare-up after hepatitis B vaccination. *Presse Med* 1998; 27:260.
 137. Demicheli V, Rivetti A, Di Pietrantonj C, Clements CJ, Jefferson T. Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review. *Journal of Viral Hepatitis* 2003; 10(5):343-4.
 138. Denis F. Hepatitis-B vaccinations in France - Survey on vaccine coverage in 2002 [French]. *Bulletin De l'Academie Nationale De Medecine* 2004; 188(1):153.

139. Dentico P, Buongiorno R, Volpe A, Zavoiani A, Pastore G, Schiraldi O. Long-term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults. *European Journal of Epidemiology* 1992; 8(5):650-5.
140. Desgrandchamps D, Siegrist CA. [Vaccination against hepatitis B]. [Review] [27 refs] [German, French]. *Sozial- Und Praventivmedizin* 1998; 43 Suppl 1:S37-40, S111-4.
141. Destefano F, Gu D, Kramarz P *et al.* Childhood vaccinations and risk of asthma. *Pediatric Infectious Disease Journal*. 21(6):498-504, 2002 Jun.
142. DeStefano F, Mullooly JP, Okoro CA *et al.* Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. *Pediatrics* 2001; 108(6):NIL_85-NIL_89.
143. DeStefano F, Verstraeten T, Jackson LA *et al.* Vaccinations and risk of central nervous system demyelinating diseases in adults. *Archives of Neurology* 2003; 60(4):504-9.
144. Devin F, Roques G, Disdier P *et al.* Occlusion of central retinal vein after hepatitis B vaccination. *Lancet* 1996; 347:1626.
145. Di Giusto C, Bernhard J. Erythema nodosum provoked by hepatitis B vaccine. *Lancet* 1986; ii:1042.
146. Di Lernia V, Lo Scocco G, Bisighini G. Erythema multiforme following hepatitis B vaccine. *Pediatr Dermatol* 1994; 11:363-4.
147. Di Paola JA, Buchanan GR. Immune thrombocytopenic purpura [Review]. *Pediatric Clinics of North America* 2002; 49(5):911-+.
148. Diaz Gonzalez M, Navia Molina O, Bravo Gonzalez JR, Pedroso Flaquet P, Urbino Lopez A. [The reactogenicity of Heberbiovac-HB vaccine at different doses]. [Spanish]. *Revista Cubana De Medicina Tropical* 1995; 47(1):65-70.
149. Diaz Gonzalez M, Rodriguez Lay L, Lopez-Chavez AU, Bravo Gonzalez JR, Pedroso Flaquet P. [Adverse reactions and immune response to Heberbiovac-HB vaccine administered to infants simultaneously with DPT and VA-MENGOC-BC]. [Spanish]. *Revista Cubana De Medicina Tropical* 1997; 49(3):196-203.
150. Diego Nunez MA, Gonzalez Menendez AE. [Vaccination against hepatitis B and multiple sclerosis (letter)]. [Spanish]. *Anales Espanoles De Pediatria* 1999; 50(1):97.
151. Dittmann S. Special address: safety of hepatitis B vaccination. *Vaccine* 2000; 18 Suppl 1:S10-1.
152. Dobson S, Scheifele D, Bell A. Assessment of a universal school-based hepatitis B vaccination program. *JAMA* 1995; 274:1209-13.
153. Domingo V, Authier FJ, Bachoud-Levi AC, Gherardi RK, Degos JD. Should hepatitis B vaccine be contra-indicated in myasthenia gravis?. *Autoimmunity* 1999; 29(2):139-40.
154. Drago F, Rebola A. Cutaneous immunologic reactions to hepatitis B virus vaccine. *Annals of Internal Medicine*. 136(10):780, 2002 May 21.
155. Drucker Y, Prayson R, Bagg A *et al.* Lymphocytic vasculitis presenting as diffuse subcutaneous edema after hepatitis B vaccine. *J Clin Rheum* 1997; 3:158-61.
156. Drueke T, Barbanel G, Jungens P *et al.* Hepatitis B antigen associated periarteritis nodosa in patients undergoing long-term hemodialysis. *Am J Med* 1980; 68:86-90.

157. Duclos P. Adverse events after hepatitis B vaccination. [Review] [32 refs]. *CMAJ* 1992; 147(7):1023-6.
158. Duclos P. Safety of immunization and adverse events following vaccination against hepatitis B. *Journal of Hepatology* 2003; 39(Suppl 1):S83-S88.
159. Durand JM, Cretel E, Morange S *et al*. Poussée lupique après vaccin recombinant contre le virus de l'hépatite B. *Rev Med Int* 1996; 17:409s-.
160. el-Reshaid K, al-Mufti S, Johny KV, Sugathan TN. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. *Vaccine* 1994; 12(3):223-34.
161. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. *Annals of the Rheumatic Diseases*. 61(7):623-625, 2002 Jul.
162. Ellenberg SS, Braun MM. Monitoring the safety of vaccines - assessing the risks. *Drug Safety*. 25(3):145-152, 2002.
163. Elling H, Skinghoj P, Elling P *et al*. Hepatitis B virus and polymyalgia rheumatica; a search for HBsAg, HbsAb, HBcAb, HBeAg, and HBeAb. *Ann Rheum Dis* 1980; 39:511-3.
164. Erbagci Z. Childhood bullous pemphigoid following hepatitis B immunization. *Journal of Dermatology* 2002; 29(12):781-5.
165. Eriksen EM, Perlman JA, Miller A *et al*. Lack of association between hepatitis B birth immunization and neonatal death. *Pediatric Infectious Disease Journal* 2004; 23(7):656-61.
166. Evans AA, London WT. Hepatitis B vaccine and liver problems in U.S. children less than 6 years old [letter]. *Epidemiology* 1999; 10(6):790-1.
167. Eyigun CP, Yilmaz S, Gul C, Sengul A, Hacibektasoglu A, Van Thiel DH. A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults. *Journal of Viral Hepatitis* 1998; 5(4):265-9.
168. Fabrizi F, Di Filippo S, Marcelli D *et al*. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. *Nephron* 1996; 72(4):536-43.
169. Fawcett H, Smith NP. Injection-site granuloma due to aluminium. *Arch Dermatol* 1984; 120:1318-22.
170. Fe A. Overview of 5-year clinical experience with a yeast-derived hepatitis B vaccine. *Vaccine* 1990; 8 (suppl):S74-S78.
171. Feely M. Hepatitis and hepatitis immunisation. [Review] [42 refs]. *Journal of the Royal Society of Health* 1997; 117(1):41-6.
172. Feldshon S, Sampliner R. Reaction to hepatitis B virus vaccine. *Annals of Internal Medicine* 1984; 100:156-7.
173. Fendrick AM, Lee JH, LaBarge C, Glick HA. Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis. *Archives of Pediatrics & Adolescent Medicine* 1999; 153(2):126-36.
174. Fernandez-Funez A, Polo Romero FJ. [Juvenile dermatomyositis concomitant with hepatitis B

- vaccination (letter)]. [Spanish]. *Medicina Clinica* 1998; 111(17):675.
175. Ferrando MF, Doutre MS, Beylot-Barry M, Durand I, Beylot C. Lichen planus following hepatitis B vaccination [letter]. *British Journal of Dermatology* 1998; 139(2):350.
 176. Ferrazi V, Jorgensen C, Sany J. Inflammatory joint disease after immunization. A report of two cases. *Rev Rhum Engl Ed* 1997; 64:227-32.
 177. Fields HA, Mahoney FJ, Margolis HS. Safety of hepatitis B vaccine [letter; comment]. *Science* 1996; 272(5262):633-4.
 178. Fineschi S. Can recombinant anti-hepatitis B vaccine be a cause of systemic lupus erythematosus? *Lupus* 2001; 10(11):830.
 179. Finielz P, Lam-Kam-Sang LF, Guiserix J. Sytemic lupus erythematosus and thrombocytopenic purpura in two members of the same family following hepatitis B vaccine. *Nephrol Dial Transplant* 1998; 13:2420-1.
 180. Fisher MA, Eklund SA. Hepatitis B vaccine and liver problems in U.S. children less than 6 years old, 1993 and 1994. *Epidemiology* 1999; 10(3):337-9.
 181. Fisher MA, Eklund SA, James SA, Lin XH. Adverse events associated with hepatitis B vaccine in US children less than six years of age, 1993 and 1994. *Annals of Epidemiology* 2001; 11(1):13-21.
 182. Fledelius HC. Unilateral papilloedema after hepatitis B vaccination in a migraine patient. A case report including forensic aspects. *Acta Ophthalmologica Scandinavica* 1999; 77(6):722-4.
 183. Flemmer M, Oldfield EC 3rd. The bald truth. *American Journal of Gastroenterology* 1999; 94(4):1104.
 184. Fourrier A, Begaud B, Alperovitch A *et al*. Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: a comparison between reported and expected number of cases. *British Journal of Clinical Pharmacology* 2001; 51(5):489-90.
 185. Frankel SK, Sullivan EJ, Brown KK. Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, and Takayasu arteritis [Review]. *Critical Care Clinics* 2002; 18(4):855-+.
 186. Fraser PA, Wilson JD. Reiter's syndrome attributed to hepatitis B immunisation [letter; comment]. *BMJ* 1994; 309(6967):1513.
 187. Freed GL, Andreae MC, Cowan AE, Katz SL. The process of public policy formulation: the case of thimerosal in vaccines. *Pediatrics*. 109(6):1153-1159, 2002 Jun.
 188. Fried M, Conen D, Conzelmann M. Uveitis after hepatitis B vaccination. *Lancet* 1987; ii:631-2.
 189. Fures J, Boucher D. Safety of hepatitis B vaccine. *Canadian Medical Association Journal* 1983; 129:17-8.
 190. Gall Y, Stalder J, Mousset S *et al*. Mise en évidence de l'aluminium dans un nodule sous-cutané secondaire à une vaccination par le Tétracoq. *Ann Dermatol Venereol* 1989; 116:80.
 191. Ganry O, Lerailler F, Vercelletto M, Chiffolleau A, Larousse C. [Peripheral facial paralysis following vaccination against hepatitis B. Apropos of a case (letter)]. [French]. *Therapie* 1992; 47(5):437-8.

192. Geier DA, Geier MR. Chronic adverse reactions associated with hepatitis B vaccination. *Annals of Pharmacotherapy* 2002; 36(12):1970-1.
193. Geier DA, Geier MR. Comment: hepatitis B vaccination safety - Authors' reply. *Annals of Pharmacotherapy* 2002; 36(10):1649-50.
194. Geier DA, Geier MR. Cutaneous immunologic reactions to hepatitis B virus vaccine - in response. *Annals of Internal Medicine* 2002; 136:780-1.
195. Geier DA, Geier MR. Gastrointestinal reactions and rotavirus vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database for 1999. A model for the calculation of the incidence rates and statistical significance of adverse events following immunization. *Hepatology* 2004; 51(56):465-9.
196. Geier DA, Geier MR. Hepatitis B vaccination and adult associated gastrointestinal reactions: a follow-up analysis. *Hepatology* 2002; 49(48):1571-5.
197. Geier DA, Geier MR. Hepatitis B vaccination and adult associated gastrointestinal reactions: A follow-up analysis. *Hepato-Gastroenterology* 2002; 49(48):1571-5.
198. Geier DA, Geier MR. Hepatitis B vaccination and arthritic adverse reactions: a followup analysis of the Vaccine Adverse Events Reporting System (VAERS) database. *Clin Exp Rheumatol* 2002; 20(1):119.
199. Geier DA, Geier MR. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database. *Clin Exp Rheumatol* 2002; 20(6):767-71.
200. Geier MR, Geier DA. Hepatitis B vaccination safety. *Annals of Pharmacotherapy* 2002; 36(3):370-4.
201. Geier MR, Geier DA, Zahalsky AC. Influenza vaccination and Guillain Barre syndrome small star, filled. *Clin Immunol* 2003; 107(2):116-21.
202. Geier MR, Geier DA, Zahalsky AC. A review of hepatitis B vaccination. *Expert Opin Drug Saf* 2003; 2(2):113-22.
203. Geier M, Geier DA. Arthritic reactions following hepatitis B vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) data from 1990 through 1997. *Clinical and Experimental Rheumatology* 2000; 18:789-90.
204. Geier M, Geier D. Immunologic reactions and hepatitis B vaccine. *Annals of Internal Medicine* 2001; 134:1155.
205. Gellin BG, Schaffner W. The risk of vaccination - The importance of "negative" studies. *New England Journal of Medicine* 2001; 344(5):372-3.
206. Germanaud J, Causse X, Trinh DH *et al*. A case of severe cytolysis after hepatitis B vaccination. *Am J Med* 1995; 98:595-6.
207. Gherardi RK. Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome. [French]. *Revue Neurologique* 2003; 159(2):162-4.
208. Gherardi RK, Coquet M, Cherin P *et al*. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. *Brain* 2001; 124(Part 9):1821-31.

209. Ghezzi A, Deplano V, Faroni J *et al.* Multiple sclerosis in children: clinical features of 149 cases. *Multiple Sclerosis* 1997; 3:43-6.
210. Giammanco G, Moiraghi A, Zotti C *et al.* Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine administered according to two different primary vaccination schedules. Multicenter Working Group. *Vaccine* 1998; 16(7):722-6.
211. Giammanco G, Pignato S, Taormina S *et al.* [Immunization efficacy and tolerance of a tetravalent vaccine against diphtheria, tetanus, pertussis (acellular) and hepatitis B]. [Italian]. *Annali Di Igiene* 1997; 9(3):209-13.
212. Girard M. Santé, thérapeutique et principe de précaution. *Experts* 2001; (52):19-26.
213. Girard M. Vaccination contre l'hépatite B. In: Rogier A. Les événements de l'année 2001 en dommage corporel. Paris: Editions Eska, 2001: 63-70.
214. Girault V. Hepatitis B, systematic vaccination recommended again [french]. *Presse Medicale*. 31(23):1059, 2002 Jun 29.
215. Gisserot O, Carsuzaa F, Marlier S, Morand JJ, Marrot E. [Lichen planus after hepatitis B vaccination. 3 new cases (letter)]. [French]. *Presse Medicale* 1997; 26(16):760.
216. Gizaris V, Roumeliotou A, Ktenas E, Papoutsakis G, Papaevangelou G. Evaluation of the immunogenicity of a recombinant vaccine against hepatitis B containing S and pre-S2 sequences using two different schedules. *Vaccine* 1993; 11(14):1445-7.
217. Goldfarb J, Medendorp SV, Garcia H, Nagamori K, Rathfon H, Krause D. Comparison study of the immunogenicity and safety of 5- and 10-microgram dosages of a recombinant hepatitis B vaccine in healthy infants [see comments]. *Pediatric Infectious Disease Journal* 1996; 15(9):764-7.
218. Goldwater P. Hypersensitivity to intradermal hepatitis B vaccine. *Lancet* 1984; (8412):1156.
219. Goolsby PL. Erythema nodosum after Recombivax HB hepatitis B vaccine. *New Eng J Med* 1989; 321:1198-9.
220. Gorbunov MA, Pavlova LI, Noslova AV *et al.* [A comparative evaluation of the immunogenicity and reactogenicity of recombinant vaccines against hepatitis B]. [Russian]. *Voprosy Virusologii* 1993; 38(5):216-8.
221. Gorbunov MA, Pavlova LI, Titov IA *et al.* [The efficacy of recombinant vaccines against hepatitis B and the results of their use in a schedule for pediatric prophylactic inoculations]. [Russian]. *Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii* 1997; (6):55-8.
222. Gout O. Vaccinations and multiple sclerosis. *Neurological Sciences* 2001; 22(2):151-4.
223. Gout O, Lyon-Caen O. [Sclerotic plaques and vaccination against hepatitis B (editorial)]. [French]. *Revue Neurologique* 1998; 154(3):205-7.
224. Gout O, Théodorou I, Liblau R *et al.* Central nervous system demyelination after recombinant hepatitis B vaccination: report of 25 cases. *Neurology* 1997; A424.
225. Gran B, Bielekova B, McFarland H *et al.* Development of multiple sclerosis after hepatitis B vaccination: an immunologic case report . *Neurology* 2000; 54 (suppl 3):A164.
226. Granel B, Disdier P, Devin F *et al.* [Occlusion of the central retinal vein after vaccination against viral hepatitis B with recombinant vaccines. 4 cases]. [French]. *Presse Medicale* 1997; 26(2):62-5.

227. Grasland A, Le Maitre F, Pouchot J, Hazera P, Bazin C, Vinceneux P. [Adult-onset Still's disease after hepatitis A and B vaccination?]. [French]. *Revue De Medecine Interne* 1998; 19(2):134-6.
228. Green C, Lakshmipathi T. A case of hepatitis related to etretinate therapy and hepatitis B vaccine. *Dermatologica* 1991; 182:119-20.
229. Green MS, Cohen D, Lerman Y *et al*. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine. *Israel Journal of Medical Sciences* 1994; 30(5-6):485-8.
230. Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. [Review] [73 refs]. *Pediatric Infectious Disease Journal* 1993; 12(5):438-45.
231. Greenberg DP, Vadheim CM, Marcy SM *et al*. Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4 and 6 months of age. The Kaiser-UCLA Vaccine Study Group. *Vaccine* 1996; 14(8):811-6.
232. Greenberg DP, Vadheim CM, Wong VK *et al*. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. *Pediatric Infectious Disease Journal* 1996; 15(7):590-6.
233. Greenberg DP, Wong VK, Partridge S, Howe BJ, Ward JI. Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age. *Pediatric Infectious Disease Journal* 2002; 21(8):769-76.
234. Grezard P, Chefai M, Philippot V, Perrot H, Faisant M. [Cutaneous lupus erythematosus and buccal aphthosis after hepatitis B vaccination in a 6-year-old child]. [French]. *Annales De Dermatologie Et De Venereologie* 1996; 123(10):657-9.
235. Grosheide PM, Schalm SW, van Os HC, Fetter WP, Heijntink RA. Immune response to hepatitis B vaccine in pregnant women receiving post-exposure prophylaxis. *European Journal of Obstetrics, Gynecology, & Reproductive Biology* 1993; 50(1):53-8.
236. Gross K, Combe C, Krüger K *et al*. Arthritis after hepatitis B vaccination. Report of three cases. *Scand J Rheumatol* 1995; 24:50-2.
237. Grotto I, Mandel Y, Ephros M *et al*. Major adverse reactions to yeast-derived hepatitis B vaccines -A review. *Vaccine* 1998; 16:329-34.
238. Guis S, Mattei JP, Liote F. Drug-induced and toxic myopathies [Review]. *Best Practice & Research in Clinical Rheumatology* 2003; 17(6):877-907.
239. Guis S, Mattei JP, Nicoli F *et al*. Identical twins with macrophagic myofasciitis: Genetic susceptibility and triggering by aluminic vaccine adjuvants? *Arthritis & Rheumatism* 2002; 47(5):543-5.
240. Guis S, Pellissier JF, Nicoli F *et al*. HLA-DRB1*01 and macrophagic myofasciitis. *Arthritis & Rheumatism* 2002; 46(9):2535-7.
241. Guiserix J. Systemic lupus erythematosus following hepatitis B vaccine. *Nephron* 1996; 74:441.
242. Gupta I, Ratho RK. Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy. *JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH* 2003; 29(2):84-6.
243. Hachulla E, Houvenagel E, Mingui A *et al*. Reactive arthritis after hepatitis B vaccination. *J*

- Rheumatol 1990; 17:1250-1.
244. Hall A, Kane M, Roure C, Meheus A. Multiple sclerosis and hepatitis B vaccine?. *Vaccine* 1999; 17(20-21):2473-5.
 245. Halsey NA, Blatter M, Bader G *et al.* Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. *Pediatric Infectious Disease Journal* 1997; 16(7):675-9.
 246. Halsey NA, Duclos P, Van Damme P, Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases. *Viral Hepatitis Prevention Board*. [Review] [0 refs]. *Pediatric Infectious Disease Journal* 1999; 18(1):23-4.
 247. Halsey NA, Moulton LH, O'Donovan JC *et al.* Hepatitis B vaccine administered to children and adolescents at yearly intervals. *Pediatrics* 1999; 103(6):1243-7.
 248. Hamard H, Hamard P, Gohier P, Roussat B, Doummar D, Iba-Zizen MT. Infantile acute optic neuritis [French]. *Bulletin De l'Academie Nationale De Medecine* 2000; 184(7):1511-21.
 249. Hanslik T, Vaillant JN, Audrain L *et al.* Systemic lupus erythematosus and adverse events related to hepatitis B vaccination: from level of evidence to prescription. [French]. *Revue De Medecine Interne* 2000; 21(9):785-90.
 250. Hanslik T, Viboud C, Flahault A. Vaccinations and multiple sclerosis. *New England Journal of Medicine* 2001; 344(23):1793-4.
 251. Harrison BJ, Thomson W, Pepper L *et al.* Patients who develop inflammatory polyarthritis (IP) after immunization are clinically indistinguishable from other patients with IP. *Br J Rheumatol* 1997; 36:366-9.
 252. Hartman S. Convulsion associated with fever following hepatitis B vaccination. *Journal of Paediatrics and Child Health* 1990; 26:64.
 253. Hasan MS, Agosti JM, Reynolds KK, Tanzman E, Treanor JJ, Evans TG. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. *Journal of Infectious Diseases* 1999; 180(6):2023-6.
 254. Hassan W, Oldham R. Reiter's syndrome and reactive arthritis in health care workers after vaccination. *Br Med J* 1994; 309:94.
 255. Heinzlef O, Moguilewski A, Roullet E. [Acute aseptic meningitis after hepatitis B vaccination (letter)]. [French]. *Presse Medicale* 1997; 26(7):328.
 256. Hernan M, Jick S, Olek M, Ascherio A, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. *Pharmacoepidemiology and Drug Safety* 2003; 12:S59-S60.
 257. Hernan M, Jick S, Olek M, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. A prospective study. *Neurology* 2004; 63:838-42.
 258. Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine [see comments]. *Lancet* 1991; 338(8776):1174-5.
 259. Hess G, Hingst V, Cseke J, Bock HL, Clemens R. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. *European Journal of Clinical Microbiology & Infectious Diseases* 1992; 11(4):334-40.

260. Hessel L. Mercury in vaccines [French]. *Bulletin De l'Academie Nationale De Medecine* 2003; 187(8):1501-10.
261. Honorati MC, Facchini A. Rheumatoid epitopes and CD4+ immunodominant regions of recombinant hepatitis B surface antigen [letter; comment]. *Journal of Rheumatology* 1999; 26(7):1636.
262. Hostetler L. Vaccinations and multiple sclerosis. *New England Journal of Medicine* 2001; 344(23):1795.
263. Hourvitz A, Mosseri R, Solomon A *et al.* Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. *Journal of Viral Hepatitis* 1996; 3(1):37-42.
264. Hudson T, Newkirk M, Gervais F *et al.* Adverse reaction to the recombinant hepatitis B vaccine. *Journal of Allergy and Clinical Immunology* 1991; 88:821-2.
265. Hutteroth T, Quast U. Aluminiumhydroxid-granulom nach hepatitis-B impfung. *DMW* 1990; 115:476.
266. Hviid A, Melbye M. Association between thimerosal-containing vaccine and autism - Reply. *Jama: Journal of the American Medical Association* 2004; 291(2):180-1.
267. Imbs JL, Decker N, Welsch M. Pharmacovigilance of hepatitis B vaccines [French]. *Bulletin De l'Academie Nationale De Medecine* 2003; 187(8):1489-98.
268. Islek I, Cengiz K, Cakir M, Kucukoduk S. Nephrotic syndrome following hepatitis B vaccination [letter]. *Pediatric Nephrology* 2000; 14(1):89-90.
269. Iwamoto J, Hakozaki Y, Sakuta H *et al.* A case of agranulocytosis associated with severe acute hepatitis B. *Hepatology Research* 2001; 21(2):181-5.
270. Jacknowitz AI. Comment: hepatitis B vaccination safety. *Annals of Pharmacotherapy* 2002; 36(10):1649.
271. Jampol LM, Becker KG. White spot syndromes of the retina: A hypothesis based on the common genetic hypothesis of autoimmune/inflammatory disease. *American Journal of Ophthalmology* 2003; 135(3):376-9.
272. Jastaniah WA, Dobson S, Lugsdin JG, Petty RE. Complex regional pain syndrome after hepatitis B vaccine. *Journal of Pediatrics* 2003; 143(6):802-4.
273. Jefferson T, Traversa G. Hepatitis b vaccination: risk-benefit profile and the role of systematic reviews in the assessment of causality of adverse events following immunisation. *Journal of Medical Virology*. 67(3):451-453, 2002 Jul.
274. Jilg W. Hepatitis-B vaccination strategy for health care workers [german]. *Internist*. 43(6):777-778, 2002 Jun.
275. Jost R. [Hepatitis vaccination of adults]. [German]. *Schweizerische Medizinische Wochenschrift. Journal Suisse De Medecine* 1998; 128(27-28):1104-9.
276. Journe F, Deschamps F, Germain ML. Vascularite et vaccination contre l'hépatite B. *Arch Mal Prof* 1995; 56:48.
277. Kakar A, Sethi PK. Guillain Barre syndrome associated with hepatitis B vaccination. *Indian*

- Journal of Pediatrics 1997; 64(5):710-2.
278. Kallinowski B, Bock HL, Clemens R, Theilmann L. [Immunogenicity and tolerance of a combined hepatitis A/B vaccine. Preliminary results with a candidate vaccine]. [German]. Deutsche Medizinische Wochenschrift 1995; 120(42):1426-9.
 279. Kanra G, Ceyhan M, Ecevit Z *et al.* Primary vaccination of infants with a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine. Pediatric Infectious Disease Journal 1995; 14(11):998-1000.
 280. Kaplanski G, Retornaz F, Durand J, Soubeyrand J. Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype [letter]. Journal of Neurology, Neurosurgery & Psychiatry 1995; 58(6):758-9.
 281. Karaali-Savrun F, Altintas A, Saip S, Siva A. Hepatitis B vaccine related-myelitis? European Journal of Neurology 2001; 8(6):711-5.
 282. Kaygusuz S, Erdemoglu AK, Koksai I. Afebrile convulsion in an adult after recombinant hepatitis B vaccination. Scandinavian Journal of Infectious Diseases. 34(4):314-315, 2002.
 283. Kear TM, Wright LS. Transient hepatitis B antigenemia in hemodialysis patients following hepatitis B vaccination. Anna Journal 1996; 23(3):331.
 284. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B (R)) - A review of its immunogenicity and protective efficacy against hepatitis B [Review]. Drugs 2003; 63(10):1021-51.
 285. Kerleau JM, Levesque H, Lair G, Lecomte F, Carrara O, Courtois H. [Is hepatitis B vaccination a new cause of necrotizing vasculitis? (letter)]. [French]. Revue De Medecine Interne 1997; 18(6):491-2.
 286. Kerr DA, Ayetey H. Immunopathogenesis of acute transverse myelitis [Review]. Current Opinion in Neurology 2002; 15(3):339-47.
 287. Khukhlovich PA, Shakhgil'dian IV, Narkevich MI *et al.* [The vaccinal prophylaxis of hepatitis B among children born to mothers with persistent HBs-antigenemia]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii 1996; (2):55-9.
 288. Kimmel SR. Vaccine adverse events: Separating myth from reality. American Family Physician 2002; 66(11):2113-20.
 289. Kirkland L. Ocular sensitivity to thimerosal: a problem with hepatitis B vaccine? Southern Medical Journal 1990; 83:497-9.
 290. Kloster B, Kramer R, Eastlund T, Grossman B, Zarvan B. Hepatitis B surface antigenemia in blood donors following vaccination [see comments]. Transfusion 1995; 35(6):475-7.
 291. Kojouharova M, Teoharov P, Bahtchevanova T, Maeva I, Eginlian A, Deneva M. Safety and immunogenicity of a yeast-derived recombinant hepatitis B vaccine in Bulgarian newborns. Infection 2001; 29(6):342-4.
 292. Lacour JP. ["Hepatitis, the vaccine, multiple sclerosis and lichen": the story and its morale (editorial; comment)]. [French]. Annales De Dermatologie Et De Venereologie 1998; 125(6-7):395-7.
 293. Lakshmi G, Reddy RP, Kumar KK, Bhavani NV, Dayanand M. Study of the safety, immunogenicity and seroconversion of a hepatitis-B vaccine in malnourished children of India.

Vaccine 2000; 18(19):2009-14.

294. Laoussadi S *et al.* Severe rheumatic disorder associated with hepatitis B virus vaccination. *Arthritis Rheum* 1998; 41 (suppl 9):S230.
295. Larche-Mochel M, Deniau C, Doignon J *et al.* Vaccination obligatoire contre l'hépatite B et sclérose en plaques. A propos d'un cas examiné à la consultation des maladies professionnelles. *Arch Mal Prof* 1994; 55:301.
296. Lasheras Carbajo MD, Palacios Diez M, Gonzalez Diego P, Martin ScapaM. A. , Cano Ruiz A, Asensio Vegas A. [A case of intense cytolysis following the administration of a hepatitis B vaccine (letter)]. [Review] [11 refs] [Spanish]. *Revista Clinica Espanola* 1999; 199(1):49-50.
297. Le Hello C. [Vasculitis associated with antiviral vaccines and antiviral agents]. [Review] [38 refs] [French]. *Pathologie Biologie* 1999; 47(3):252-6.
298. Le Hello C, Cohen P, Bousser MG, Letellier P, Guillevin L. Suspected hepatitis B vaccination related vasculitis. *Journal of Rheumatology* 1999; 26(1):191-4.
299. Le Hello C, Cohen P, Guillevin L. Vasculite leucocytoclasique après une vaccination contre l'hépatite B. *Revue De Medecine Interne* 1995; 16 (suppl 1):P174.
300. Lear J, English J. Anaphylaxis after hepatitis B vaccination. *Lancet* 1995; 345:1249.
301. Lee CY, Lee PI, Huang LM, Chen JM, Chang MH. A simplified schedule to integrate the hepatitis B vaccine into an expanded program of immunization in endemic countries. *Journal of Pediatrics* 1997; 130(6):981-6.
302. Lee JM, Sundel RP, Liang MG. Fibroblastic rheumatism: Case report and review of the literature [Review]. *Pediatric Dermatology* 2002; 19(6):532-5.
303. Lee PI, Lee CY, Huang LM, Chen JM, Chang MH. A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants. *Vaccine* 1995; 13(17):1685-9.
304. Lee SD, Chan CY, Yu MI, Lu RH, Chang FY, Lo KJ. Hepatitis B vaccination in patients with chronic hepatitis C. *Journal of Medical Virology* 1999; 59(4):463-8.
305. Lefort A, Dachary D, Vergier B, Boiron G. [Lichen planus and vaccination against hepatitis B]. [French]. *Annales De Dermatologie Et De Venereologie* 1995; 122(10):701-3.
306. Legoff P, Fauquert P, Youinou P *et al.* Périartérite noueuse après vaccination contre l'hépatite B. *Presse Méd* 1988; 17:1763.
307. Legout L, Hachulla E, Chérin P *et al.* Maladies auto-immunes et vaccination contre l'hépatite B: faut-il vacciner nos patients? *Rev Méd Int* 2001; 22:402-5.
308. Lemaire V. Fréquence des effets secondaires de la vaccination contre l'hépatite B chez 43 618 sujets. *Concours Médical* 1992; 114:2092.
309. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. [Review] [117 refs]. *New England Journal of Medicine* 1997; 336(3):196-204.
310. Leport Y. Lichen plan et vaccin contre l'hépatite B. *Nouv Dermatol* 1995; 14:594.
311. Leroux-Roels G, Desombere I, De Tollenaere G *et al.* Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young,

- healthy adults. *Vaccine* 1997; 15(16):1724-31.
312. Lewis E, Shinefield HR, Woodruff BA *et al.* Safety of neonatal hepatitis B vaccine administration. *Pediatric Infectious Disease Journal* 2001; 20(11):1049-54.
 313. Lieberman JM, Greenberg DP. Hepatitis A and B vaccines in children. [Review] [131 refs]. *Advances in Pediatric Infectious Diseases* 1996; 11:333-63.
 314. Lilic D, Ghosh SK. Liver dysfunction and DNA antibodies after hepatitis B vaccination. *Lancet* 1994; 344:1292-3.
 315. Limas C, Limas CJ. Lichen planus in children: a possible complication of hepatitis B vaccines. *Pediatric Dermatology*. 19(3):204-209, 2002 May-Jun.
 316. Lin J, Chang M, Hsu C *et al.* A rare association between hepatitis B virus vaccination and Guillain-Barré syndrome. A case report. *Chinese Journal of Gastroenterology* 1989; 6:229-32.
 317. Linder N, Raz M, Sirota L *et al.* Unexplained fever in neonates may be associated with hepatitis B vaccine. *Archives of Disease in Childhood Fetal & Neonatal Edition* 1999; 81(3):F206-7.
 318. Lliminana C, Soler JA, Melo M, Roig I. [Hemolytic anemia and thrombocytopenic purpura after the administration of the recombinant hepatitis B vaccine (letter)]. [Spanish]. *Medicina Clinica* 1999; 113(1):39.
 319. Lohiya G. Asthma and urticaria after hepatitis B vaccination. *Western Journal of Medicine* 1987; 147:341.
 320. Lugoboni F, Migliozi S, Schiesari F *et al.* Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. *Vaccine* 1997; 15(9):1014-6.
 321. Luman ET, Fiore AE, Strine TW, Barker LE. Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage. *JAMA* 2004; 291(19):2351-8.
 322. Lumbiganon P, Kowsuwan P, Lumbiganon P, Taksaphan S, Panamonta M, Assateerawatts A. Comparison of immunogenicity of hepatitis B vaccine between low and normal birth weight infants. *Asian Pacific Journal of Allergy & Immunology* 1992; 10(1):61-3.
 323. Luosujarvi RA, Husman TM, Seuri M *et al.* Joint symptoms and diseases associated with moisture damage in a health center. *Clinical Rheumatology* 2003; 22(6):381-5.
 324. Lévy-Bruhl D, Rebičre I, Desenclos J *et al.* Comparaison entre les risques de premières atteintes démyélinisantes centrales aiguës et les bénéfices de la vaccination contre l'hépatite. *BEH* 1999; 9:1-4.
 325. Macario F, Freitas L, Correia J *et al.* Nephrotic syndrome after recombinant hepatitis B vaccine. *Clin Nephrol* 1995; 43:349.
 326. MacIntyre CR. Hepatitis b vaccine: risks and benefits of universal neonatal vaccination. *Journal of Paediatrics & Child Health*. 37(3):215-217, 2001 Jun.
 327. MacIntyre CR, Leask J. Immunization myths and realities: Responding to arguments against immunization. *Journal of Paediatrics & Child Health* 2003; 39(7):487-91.
 328. Mahassin F, Algayres JP, Valmary J *et al.* Myélite aiguë après vaccination contre l'hépatite B. *Presse Medicale* 1993; 22(40):1997-8.

329. Maillefert JF, Farge P, Gazet-Maillefert MP, Tavernier C. Mental nerve neuropathy as a result of hepatitis B vaccination. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, & Endodontics* 1997; 83(6):663-4.
330. Maillefert JF, Sibia J, Toussiro E *et al.* Rheumatic disorders developed after hepatitis B vaccination. *Rheumatology (Oxford)* 1999; 38(10):978-83.
331. Maillefert JF, Tavernier C, Sibia J, Vignon E. Exacerbation of systemic lupus erythematosus after hepatitis B vaccination: comment on the article by Battafarano et al and the letter by Senecal et al [letter]. *Arthritis & Rheumatism* 2000; 43(2):468-9.
332. Mamoux V, Dumont C. Lupus erythémateux disséminé et vaccination contre l'hépatite B. *Arch Pediatr* 1994; 1:307-8.
333. Manna R, De Santis A, Oliviero A *et al.* Leucoencephalitis after recombinant hepatitis B vaccine. *Journal of Hepatology* 1996; 24:764-5.
334. Marcuse EK, MacDonald NE. Vaccine injury--no reports [letter]. *Pediatrics* 1997; 99(1):144.
335. Marsano LS, West DJ, Chan I *et al.* A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. *Vaccine* 1998; 16(6):624-9.
336. Marsaudon E, Barrault MF. [Meningeal reaction after vaccination against hepatitis B (letter)]. [French]. *Presse Medicale* 1996; 25(32):1561-2.
337. Marshall E. A shadow falls on hepatitis B vaccination effort [news]. *Science* 1998; 281(5377):630-1.
338. Marshall GS, Gellin BG. Challenges to vaccine safety [Review]. *Primary Care* 2001; 28(4):853-+.
339. Martinez E, Domingo P. Evan's syndrome triggered by recombinant hepatitis B vaccine. *Clin Infect Dis* 1992; 15:1051.
340. Marwick C, Mitka M. Debate revived on hepatitis B vaccine value [news]. *JAMA* 1999; 282(1):15-7.
341. Masse I, Descoffres MC. [Hypersensitivity vasculitis after hepatitis B vaccination (letter)]. [French]. *Presse Medicale* 1998; 27(20):965-6.
342. Mathei C, Van Damme P, Meheus A. Hepatitis B vaccine administration: comparison between jet-gun and syringe and needle. *Vaccine* 1997; 15(4):402-4.
343. Mathieu E, Fain O, Krivitzky A. Cryoglobulinemia after hepatitis B vaccination [letter]. *New England Journal of Medicine* 1996; 335(5):355.
344. McKenna KE. Eczematous reaction to hepatitis B vaccine. *Contact Dermatitis* 1999; 40(3):158-9.
345. McMahon BJ, Helminiak C, Wainwright RB *et al.* Frequency of adverse reactions to hepatitis B vaccine in 43, 618 persons. *Am J Med* 1992; 92:254-6.
346. Merigou D, Leaute-Labreze C, Louvet S, Bioulac-Sage P, Taieb A. [Lichen planus in children: role of the campaign for hepatitis B vaccination (see comments)]. [French]. *Annales De Dermatologie Et De Venereologie* 1998; 125(6-7):399-403.
347. Merkel PA. Drug-induced vasculitis [Review]. *Rheumatic Diseases Clinics of North America* 2001; 27(4):849-+.

348. Meyboom RH, Fucik H, Edwards IR. Thrombocytopenia reported in association with hepatitis B and A vaccines. *Lancet* 1995; 345:1638.
349. Meyboom R. Is there a hepatitis B vaccine induced auto immune syndrome? *Signal* 1999; (4-12).
350. Mikaeloff Y *et al.* La sclérose en plaques de l'enfant. *La Lettre Du Neurologue* 2002; 6:201-4.
351. Milstien J, Kuritsky J. Erythema multiform and hepatitis B immunization. *Archives of Dermatology* 1986; 112:511-2.
352. Miron DFDHP. Kawasaki disease in an infant following immunisation with hepatitis B vaccine. *Clinical Rheumatology* 2003; 22:461-3.
353. Monteyne P, Andre FE. Is there a causal link between hepatitis B vaccination and multiple sclerosis?. *Vaccine* 2000; 18(19):1994-2001.
354. Mouthon L, Le Toumelin P, Andre MH, Gayraud M, Casassus P, Guillevin L. Polyarteritis nodosa and Churg-Strauss angiitis - Characteristics and outcome in 38 patients over 65 years. *Medicine* 2002; 81(1):27-40.
355. Mphahlele MJ, Burnett RJ, Kyaw T, Schoeman HS, Aspinall S. Immunogenicity and safety of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB) in South African children. *South African Medical Journal* 2004; 94(4):280-1.
356. Muller A, Kertzsch F, Kiefel V, Lenk H. Thrombocytopenic purpura: adverse reaction to a combined immunisation (recombinant hepatitis B and measles-mumps-rubella-vaccine) and after therapy with Co-trimoxazole. *European Journal of Pediatrics* 1999; 158 Suppl 3:S209-10.
357. Murdoch DL, Goa K, Figgitt DP. Combined hepatitis a and B vaccines - A review of their immunogenicity and tolerability. *Drugs* 2003; 63(23):2625-49.
358. Nadeau SE. Neurologic manifestations of systemic vasculitis. *Neurologic Clinics* 2002; 20(1):123-+.
359. Nadler JP. Multiple sclerosis and hepatitis B vaccination [letter]. *Clinical Infectious Diseases* 1993; 17(5):928-9.
360. Nagafuchi S, Tokiyam K, Kashiwagi S *et al.* Eosinophilia after intradermal hepatitis B vaccination. *Lancet* 1993; 342:998.
361. Neau D, Bonnet F, Michaud M *et al.* Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases. *Scandinavian Journal of Infectious Diseases* 1998; 30(2):115-8.
362. Neau D, Laharie D, Zerbib F *et al.* Vascularite grave après vaccination contre l'hépatite B: une observation. *Rev Méd Int* 1996; 17 (suppl 1):P75.
363. Niu MT, Davis DM, Ellenberg S. Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System. *Pediatric Infectious Disease Journal* 1996; 15(9):771-6.
364. Niu MT, Rhodes P, Salive M *et al.* Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). *Journal of Clinical Epidemiology* 1998; 51(6):503-10.
365. Niu MT, Salive ME, Ellenberg SS. Neonatal deaths after hepatitis B vaccine: the vaccine adverse

- event reporting system, 1991-1998. *Archives of Pediatrics & Adolescent Medicine* 1999; 153(12):1279-82.
366. Noble JP, de Gennes C, Bousquet O. [Skin diseases related to hepatitis B vaccine (letter)]. [French]. *Gastroenterologie Clinique Et Biologique* 1997; 21(1):87.
367. Noel I, Galloway A, Ive F. Hypersensitivity to thiomersal in hepatitis B vaccine. *Lancet* 1991; 338:705.
368. Nuevo H, Nascimento-Carvalho CMC, Athayde-Oliveira CP, Lyra I, Moreira LMO. Thrombocytopenic purpura after hepatitis B vaccine: Case report and review of the literature. *Pediatric Infectious Disease Journal* 2004; 23(2):183-4.
369. Nutini M, Marie F, Loucq C *et al.* Hepatitis B vaccin. Clinical experience and safety. *Lancet* 1983; ii:1301.
370. Offit PA, Hackett CJ. Addressing parents' concerns: Do vaccines cause allergic or autoimmune diseases? *Pediatrics* 2003; 111(3):653-9.
371. Offit PA, Jew RK. Addressing parents' concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals? *Pediatrics* 2003; 112(6):1394-401.
372. Okoth FA, Kaiguri PM, Twei J *et al.* Human plasma derived hepatitis B vaccine: Kenyan experience. *East African Medical Journal* 1998; 75(11):647-8.
373. Older SA, Battafarano DF, Enzenauer RJ. Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. *Semin Arthritis Rheum* 1999; 29:131-9.
374. Orlando MP, Masieri S, Pascarella MA, Ciofalo A, Filiaci F. Sudden hearing loss in childhood consequent to hepatitis B vaccination: a case report. *Annals of the New York Academy of Sciences* 1997; 830:319-21.
375. Ory J, Wiest F, BD *et al.* Hepatitis B vaccine and multiple sclerosis. Immunological risks. *Ann Med Nancy Est* 1995; 34:243.
376. Ozdemir S, Bakkaloglu A, Oran O. Nephrotic syndrome associated with recombinant hepatitis B vaccination: a causal relationship or just a mere association? [letter]. *Nephrology, Dialysis, Transplantation* 1998; 13(7):1888-9.
377. Pande H, Lacy BE, Crowell MD. Inflammatory causes of gastroparesis: Report of five cases. *Digestive Diseases & Sciences* 2002; 47(12):2664-8.
378. Papaevangelou G, Karvelis E, Alexiou D *et al.* Evaluation of a combined tetravalent diphtheria, tetanus, whole-cell pertussis and hepatitis B candidate vaccine administered to healthy infants according to a three-dose vaccination schedule. *Vaccine* 1995; 13(2):175-8.
379. Papo T. Macrophagic myofasciitis: focal or systemic? *Joint Bone Spine* 2003; 70(4):242-5.
380. Papo T. Reply to the letter from Sandrine Guis and Jean Roudier about "Macrophagic myofasciitis: focal or systemic?". *Joint Bone Spine* 2004; 71(2):164-5.
381. Pennesi M, Torre G, Del Santo M, Sonzogni A. Glomerulonephritis after recombinant hepatitis B vaccine. *Pediatric Infectious Disease Journal* 2002; 21(2):172-3.
382. Petersen KM, Bulkow LR, McMahon BJ *et al.* Duration of hepatitis B immunity in low risk children

- receiving hepatitis B vaccinations from birth. *Pediatric Infectious Disease Journal* 2004; 23(7):650-5.
383. Petousis-Harris H, Turner N. Hepatitis B vaccination and diabetes [letter]. *New Zealand Medical Journal* 1999; 112(1093):303-4.
 384. Petruff CA, Bedford A, Gordon FD, Chopra S. Hepatitis vaccines. [Review] [115 refs]. *Digestive Diseases* 1997; 15(1-2):1-22.
 385. Peyriere H, Hillaire-Buys D, Pons M, Navarre C, Davy JM, Blayac JP. [Acute pericarditis after vaccination against hepatitis B: a rare effect to be known (letter)]. [French]. *Revue De Medecine Interne* 1997; 18(8):675-6.
 386. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. *Lancet* 2002; 360(9347):1737-41.
 387. Pichichero ME, Quick LS. Clinical evaluation of Pediarix: A new pediatric combination vaccine. *Clinical Pediatrics* 2003; 42(5):393-400.
 388. Pielak K. Hep B immunization for children. *Canadian Nurse* 1995; 91(5):49-50.
 389. Pierchalla P, Petri H, Ruping K *et al.* Urticaria after H-Bvax injection due to hypersensitivity to thiomersal (merthiolate). *Allergologie* 1987; 10:97-9.
 390. Pirmohamed M, Winstanley P. Hepatitis B vaccine and neurotoxicity. *Postgraduate Medical Journal* 1997; 73(861):462-3.
 391. Piyasirisilp S, Hemachudha T. Neurological adverse events associated with vaccination. *Current Opinion in Neurology*. 15(3):333-338, 2002 Jun.
 392. Poirriez J. Is the strategy of universal hepatitis B vaccination necessary in low-endemic countries. *Scandinavian Journal of Gastroenterology* 1998; 33:897-9.
 393. Poirriez J. A new method for risk analysis of vaccines. *Vaccine* 1999; 17:2335.
 394. Poirriez J. A preliminary experiment of absorption of antinuclear antibodies by the hepatitis B components, in a case of neurolupus. *Vaccine* 2004; 22:3166-8.
 395. Poirriez J. Quelques commentaires sur la vaccination contre l'hépatite B en France. *Presse Medicale* 1999; 28:1242-4.
 396. Poirriez J. Some questions to be raised about the hepatitis B vaccine. *Vaccine* 2002; 20:1696-8.
 397. Poovorawan Y, Theamboonlers A, Sanpavat S, Chongsrisawat V, Willems P, Safary A. Comparison study of combined DTPw-HB vaccines and separate administration of DTPw and HB vaccines in Thai children. *Asian Pacific Journal of Allergy & Immunology* 1999; 17(2):113-20.
 398. Pope JE, Stevens A, Howson W, Bell DA. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. *Journal of Rheumatology* 1998; 25(9):1687-93.
 399. Poullin P, Gabriel B. Thrombocytopenia purpura after recombinant hepatitis B vaccine. *Lancet* 1994; 34:1293.
 400. Poulton JK, Kauffman CL, Lutz LL, Sina B. Solitary mastocytoma arising at a hepatitis B vaccination site. *Cutis* 1999; 63(1):37-40.

401. Poutasi K. Immunisation and diabetes [letter; comment]. *New Zealand Medical Journal* 1996; 109(1026):283.
402. Pride MW, Bailey CR, Muchmore E, Thanavala Y. Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene, a hepatitis B vaccine containing pre-S1, pre-S2 gene products. *Vaccine* 1998; 16(6):543-50.
403. Proell S, Maiwald H, Nothdurft HD *et al.* Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity. *Journal of Travel Medicine*. 9(3):122-126, 2002 May-Jun.
404. Pusel B, Will F, Grosshans E. Lichen plan et vaccination contre l'hépatite B. *Nouv Dermatol* 1993; 12:709-10.
405. Quaglio G, Talamini G, Lugoboni F *et al.* Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. *Addiction* 2002; 97(8):985-92.
406. Rabaud C, Barbaud A, Trechot P. First case of erythralgia related to hepatitis B vaccination. *Journal of Rheumatology* 1999; 26:233-4.
407. Rajendran V, Brooks A. Symptomatic reaction to hepatitis B vaccine with abnormal liver function values. *Br Med J* 1985; 290:1476-7.
408. Randolph W, Viswanath K. Lessons learned from public health mass media campaigns: Marketing health in a crowded media world. *Annual Review of Public Health*. 25:419-437, 2004.
409. Ranieri VM, Dell'Erba A, Gentile A *et al.* Liver inflammation and acute respiratory distress syndrome in a patient receiving hepatitis B vaccine: a possible relationship?. *Intensive Care Medicine* 1997; 23(1):119-21.
410. Rau R, Karger T, Herborn G. Two cases of chronic polyarthritis after hepatitis B vaccination. *Zeitschrift Fur Rheumatologie* 1984; 43:213.
411. Raz R, Dagan R, Gallil A, Brill G, Kassis I, Koren R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. *Vaccine* 1996; 14(3):207-11.
412. Reborá A, Rongioletti F, Drago F, Parodi. Lichen planus as a side effect of HBV vaccination [editorial] [published erratum appears in *Dermatology* 1999;198(2):222]. [Review] [16 refs]. *Dermatology* 1999; 198(1):1-2.
413. Reddy PA, Gupta I, Ganguly NK. Hepatitis-B vaccination in pregnancy: safety and immunogenic response in mothers and antibody transfer to neonates. *Asia-Oceania Journal of Obstetrics & Gynaecology* 1994; 20(4):361-5.
414. Rees S, Gibson J, Forsyth A, Wray D. Thiomersal sensitivity in health care workers [letter]. *British Dental Journal* 1997; 183(11-12):395.
415. Reinke CM, Breikreutz J, Leuenberger H. Aluminium in over-the-counter drugs - Risks outweigh benefits? [Review]. *Drug Safety* 2003; 26(14):1011-25.
416. Renard JL, Guillamo JS, Ramirez JM, Taillia H, Felten D, Buisson Y. [Acute transverse cervical myelitis following hepatitis B vaccination. Evolution of anti-HBs antibodies]. [French]. *Presse Medicale* 1999; 28(24):1290-2.
417. Reuman PD, Sawyer MH, Kuter BJ, Matthews H. Safety and immunogenicity of concurrent

- administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group. *Pediatric Infectious Disease Journal* 1997; 16(7):662-7.
418. Reuten D *et al.* Neuralgic amyotrophy following recombination DNA hepatitis B vaccination. *Muscle and Nerve* 1990; 13:461.
 419. Ribera E, Dukta A. Polyneuropathy associated with administration of hepatitis B vaccine. *New England Journal of Medicine* 1983; 309:614.
 420. Ricci G, Patrizi A, Neri I, Specchia F, Tosti G, Masi M. Gianotti-Crosti syndrome and allergic background. *Acta Dermato-Venereologica* 2003; 83(3):202-5.
 421. Rich JD, Ching CG, Lally MA *et al.* A review of the case for hepatitis B vaccination of high-risk adults [Review]. *American Journal of Medicine* 2003; 114(4):316-8.
 422. Rickert D, Deladisma A, Yusuf H, Averhoff F, Brink E, Shih S. Adolescent immunizations - Are we ready for a new wave? *American Journal of Preventive Medicine* 2004; 26(1):22-8.
 423. Rietschel RL, Adams RM. Reactions to thimerosal in hepatitis B vaccines. *Dermatol Clin* 1990; 8:161-4.
 424. Riley S, Tong CY, Rutherford PA. Spurious hepatitis B surface antigen detection in a haemodialysis patient [letter] [see comments]. *Nephrology, Dialysis, Transplantation* 1998; 13(7):1897-8.
 425. Rogerson SJ, Nye FJ. Hepatitis B vaccine associated with erythema nodosum and polyarthritis. *Br Med J* 1990; 301:345.
 426. Rogier A. Les événements de l'année 2001 en dommage corporel. In: Girard M. *Vaccination contre l'hépatite B*. Paris: Editions Eska, 2001: 63-70.
 427. Ronchi F, Cecchi P, Falcioni F *et al.* Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine. *Archives of Disease in Childhood* 1998; 78(3):273-4.
 428. Rosman AS, Basu P, Galvin K, Lieber CS. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. *American Journal of Medicine* 1997; 103(3):217-22.
 429. Ross DW. Infectious vaccines. *Archives of Pathology & Laboratory Medicine* 1998; 122(1):100-1.
 430. Roulet E. La sclérose en plaques de l'enfant. *Rev Neurol* 1998; 154:619-22.
 431. Roulet E, Verdier-Taillefer M, Caillat S *et al.* Multiple sclerosis with early onset: a case-control study. *Neurology* 1995; 45 (suppl 4):A333.
 432. Roussat B, Gohier P, Doummar D *et al.* Acute optic neuritis in children: clinical features and treatment. A study of 20 cases (28 eyes) [French]. *Journal Francais d Ophthalmologie* 2001; 24(1):36-44.
 433. Ruggieri M, Polizzi A, Pavone L *et al.* Multiple sclerosis in children under 6 years of age. *Neurology* 1999; 53:478-84.
 434. Rustgi VK, Schlepner CJ, Krause DS. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults. *Vaccine* 1995; 13(17):1665-8.

435. Rutschmann OT, McCrory DC, Matchar DB. Immunization and MS - A summary of published evidence and recommendations. *Neurology* 2002; 59(12):1837-43.
436. Saadoun D, Cacoub P, Mahoux D *et al.* Vasculites postvaccinales: à propos de trois observations. *Rev Med Int* 2001; 22:172-6.
437. Sadvnick AD, Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis [letter]. *Lancet* 2000; 355(9203):549-50.
438. Saliou P, Ajjan N, Guerin N. Effectiveness and safety of immunizations in preterm infants [french]. *Archives De Pediatrie.* 9(6):629-637, 2002 Jun.
439. Santagostino E, Mannucci PM, Gringeri A *et al.* Accelerated schedule of hepatitis B vaccination in patients with hemophilia. *Journal of Medical Virology* 1993; 41(2):95-8.
440. Saywell CA, Wittal RA, Kossard S. Lichenoid reaction to hepatitis B vaccination. [Review] [13 refs]. *Australasian Journal of Dermatology* 1997; 38(3):152-4.
441. Schiff GM, Sherwood JR, Zeldis JB, Krause DS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. *Journal of Adolescent Health* 1995; 16(1):12-7.
442. Schuh T, Rocken M, Schmoeckel C, Degitz K. Lichen planus after hepatitis B vaccination [German]. *Hautarzt* 2002; 53(10):650-1.
443. Schupp P, Vente C. Lichen planus following hepatitis B vaccination [letter]. *International Journal of Dermatology* 1999; 38(10):799-800.
444. Seal D, Ficker L, Wright B *et al.* The case against thiomersal. *Lancet* 1991; 338:315-6.
445. Sebag O, Bolla G, Bebin B, Sebag F. [Exacerbation of chronic juvenile arthritis induced by hepatitis B vaccination (letter)]. [French]. *Archives De Pediatrie* 1998; 5(9):1046.
446. Senecal JL, Bertrand C, Coutlee F. Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy: comment on the article by Battafarano *et al* [letter; comment]. *Arthritis & Rheumatism* 1999; 42(6):1307-8.
447. Senejoux A, Roulot D, Belin C, Tsakiris L, Rautureau J, Coste T. [Acute myelitis after immunization against hepatitis B with recombinant vaccine (letter)]. [French]. *Gastroenterologie Clinique Et Biologique* 1996; 20(4):401-2.
448. Seneviratne U. Guillain-Barre syndrome [Review]. *Postgraduate Medical Journal* 2000; 76(902):774-82.
449. Shapiro E, Burd JK. Can immunization precipitate connective tissue disease? Report of 5 cases of systemic lupus erythematosus and review of the literature - Comment. *Seminars in Arthritis & Rheumatism* 2000; 30(3):215-6.
450. Shaw F, Graham D, Guess H *et al.* Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. *American Journal of Epidemiology* 1988; 127:337-52.
451. Shenoy KA, Adhikari MRP, Chakrapani M, Shenoy D, Pillai A. Pancytopenia after recombinant hepatitis B vaccine - An Indian case report. *British Journal of Haematology* 2001; 114(4):955.

452. Shih HH, Chang MH, Hsu HY, Lee PI, Ni YH, Chen DS. Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in taiwan. *Pediatric Infectious Disease Journal* 1999; 18(5):427-32.
453. Shoenfeld Y, Aharon-Maor A, Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. *Clinical and Experimental Rheumatology* 2000; 18:181-4.
454. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison?. [Review] [97 refs]. *Journal of Autoimmunity* 2000; 14(1):1-10.
455. Sibilia J, Maillefert JF. Vaccination and rheumatoid arthritis. *Annals of the Rheumatic Diseases*. 61(7):575-576, 2002 Jul.
456. Sicard D. [Vaccination against hepatitis B or chasing shadows (editorial)]. [French]. *Revue De Medecine Interne* 1999; 20(2):119-20.
457. Siegrist CA. Vaccine adjuvants and macrophagic myofasciitis [French]. *Bulletin De L Academie Nationale De Medecine* 2003; 187(8):1511-8.
458. Sievers EJ, Heyneman CA. Relationship between vaccinations and multiple sclerosis. *Annals of Pharmacotherapy* 2002; 36(1):160-2.
459. Silvers L, Ellenberg S, Wise R *et al*. The epidemiology of fatalities reported to the vaccine event reporting system 1990-1997. *Pharmacoepidemiol Drug Saf* 2001; 10:279-85.
460. Singh S, Sharma DR. Tolerability of a recombinant DNA hepatitis B vaccine--results of post-marketing surveillance. *Journal of Communicable Diseases* 1999; 31(1):53-5.
461. Sinsawaiwong S TP. Guillain-Barre syndrome following recombinant hepatitis B vaccine and literature review. *J Med Assoc Thai* 2000; 83:1124-6.
462. Skowron F, Grezard P, Berard F, Balme B, Perrot H. Persistent nodules at sites of hepatitis B vaccination due to aluminium sensitization. *Contact Dermatitis* 1998; 39(3):135-6.
463. Snider G. A possible systemic reaction to hepatitis B vaccine. *JAMA* 1985; 253:1260-1.
464. Song HK, Kim HC, Yun YH. Acute Myelitis after hepatitis B vaccination. *Journal of Korean Medical Science* 1997; 12(3):249-51.
465. Soubeyrand B, Boisnard F, Bruel M *et al*. [Central nervous system demyelinating disease following hepatitis B vaccination with GenHevac B. Review of ten years of spontaneous notifications (1989-1998)]. [French]. *Presse Medicale* 2000; 29(14):775-80.
466. Soubrier M, Dubost JJ, Bielsa C *et al*. Polyarthrite érosive déclenchée par une vaccination contre l'hépatite B. *Presse Med* 1997; 26:75.
467. Spiegel DM, Martin G, Bispham B, Smith M, Jensen K, Chonchol M. Rapid loss of hepatitis B immunity in hemodialysis patients. *Dialysis & Transplantation* 2004; 33(3):122-+.
468. Squarcione S, Pompa MG, Vellucci L. Morbidity from hepatitis B after introduction of nationwide immunisation in Italy [letter]. *Lancet* 1997; 350(9071):114.
469. Stephen J *et al*. Hepatitis B vaccine associated with erythema nodosum and polyarthritits. *BMJ* 1990; 301:345.
470. Stewart O, Chang B, Bradbury J. Simultaneous administration of hepatitis B and polio vaccines

- associated with bilateral optic neuritis [letter]. *British Journal of Ophthalmology* 1999; 83(10):1200-1.
471. Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. *JAMA* 1994; 271(20):1602-5.
 472. Stroffolini T, Mele A, Tosti ME *et al.* The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. *Journal of Hepatology* 2000; 33(6):980-5.
 473. Struve J, Aronsson B, Frenning B, Granath F, von Sydow M, Weiland O. Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. *Scandinavian Journal of Infectious Diseases* 1992; 24(4):423-9.
 474. Sturkenboom MCJM, Fourrier A. Vaccinations and multiple sclerosis. *New England Journal of Medicine* 2001; 344(23):1794.
 475. Suzuki H, Iino S, Shiraki K *et al.* Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing. *Vaccine* 1994; 12(12):1090-6.
 476. Tacket CO, Kelly SM, Schodel F *et al.* Safety and immunogenicity in humans of an attenuated *Salmonella typhi* vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system [published erratum appears in *Infect Immun* 1997 Sep;65(9):3981]. *Infection & Immunity* 1997; 65(8):3381-5.
 477. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. *Vaccine* 1999; 17(22):2826-9.
 478. Tartaglino L, Heiman-Patterson T, Friedman D *et al.* MR imaging in a case of postvaccination myelitis. *American Journal of Neuroradiology* 1995; 16:561-2.
 479. Tejedor Torres JC, Reyes Pecharroman S, Perez Rivilla A *et al.* [The long-term efficacy of a recombinant hepatitis B vaccine in newborns]. [Spanish]. *Anales Espanoles De Pediatria* 1993; 39(3):243-7.
 480. Thivolet C, Vialettes B, Boitard C, Bringer J. [Absence of evidence of a possible connection vaccination for hepatitis B and the development of diabetes type 1. Report of a group of ALFEDIAM experts]. [Review] [29 refs] [French]. *Diabetes & Metabolism* 1999; 25(5):441-5.
 481. Thoelen S, Van Damme P, Mathei C *et al.* Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. *Vaccine* 1998; 16(7):708-14.
 482. Thomas AR, Fiore AE, Corwith HL, Cieslak PR, Margolis HS. Hepatitis B vaccine coverage among infants born to women without prenatal screening for hepatitis B virus infection: effects of the Joint Statement on Thimerosal in Vaccines. *Pediatric Infectious Disease Journal* 2004; 23(4):313-8.
 483. Thompson SC, Norris M. Immunogenicity and reactogenicity of a combined hepatitis A-hepatitis B vaccine in adolescents. *International Journal of Infectious Diseases* 1998; 2(4):193-6.
 484. Tillmann HL, Schwarz A. Virus associated glomerulonephritis [German]. *Internist* 2003; 44(9):1098-106.

485. Tilzey AJ, Laider P, Benatvala J. Reactogenicity and immunogenicity of yeast-derived recombinant DNA hepatitis B in healthy young adults.
486. Tishler M, Shoenfeld Y. Vaccination may be associated with autoimmune diseases. *Israel Medical Association Journal: Imaj* 2004; 6(7):430-2.
487. Toft J, Larsen S, Toft H. Subacute thyroiditis after hepatitis B vaccination [letter]. *Endocrine Journal* 1998; 45(1):135.
488. Topaloglu H, Berker M, Kansu T *et al.* Optic neuritis and myelitis after booster tetanus toxoid vaccination. *Lancet* 1992; 339:178-9.
489. Tosti ME, Traversa G, Bianco E, Mele A. Multiple sclerosis and vaccination against hepatitis b: analysis of risk benefit profile. *Italian Journal of Gastroenterology & Hepatology* 1999; 31(5):388-91.
490. Tourbah A, Gout O, Liblau R *et al.* Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS?. *Neurology* 1999; 53(2):396-401.
491. Toussirot E, Lohse A, Wening D *et al.* Sjögren's syndrome occurring after hepatitis B vaccination. *Arthritis and Rheumatism* 2000; 43:2139-40.
492. Touzé E, Fourrier A, Rue-Fenouche C *et al.* Hepatitis B vaccination and first central nervous system demyelinating event: a case control study. *Neuroepidemiology* 2002; 21:180-6.
493. Touzé E, Gout O, Verdier-Taillefer MH, Lyon-Caen O, Alperovitch A. [The first episode of central nervous system demyelination and hepatitis B virus vaccination]. [French]. *Revue Neurologique* 2000; 156(3):242-6.
494. Treves R, Lacoste L, Bontoux D *et al.* Polyarthrite nodulaire érosive déclenchée par une vaccination contre l'hépatite B. *Presse Med* 1997; 26:670.
495. Trevisan G, Stinco G. Lichen ruber planus following HBV vaccination. *Acta Dermatol Venereol* 1993; 73:73.
496. Trevisani F, Gattinara GC, Caraceni P *et al.* Transverse myelitis following hepatitis B vaccination [letter]. *Journal of Hepatology* 1993; 19(2):317-8.
497. Tudela P, Marti S, Bonal J. Systemic lupus erythematosus and vaccination against hepatitis B. *Nephron* 1992; 62:236.
498. Tuohy P. Guillain Barre syndrome following immunization with synthetic hepatitis B. *New Zealand Medical Journal* 1989; 102:114-5.
499. Turner-Stokes LIDA. Immunisation of patients with rheumatoid arthritis and systemic lupus erythematosus. *Ann Rheu Dis.* 1988; 47:529-31.
500. Usman A, Kimyai-Asadi A, Stiller MJ, Alam M. Lichenoid eruption following hepatitis B vaccination: First North American case report. *Pediatric Dermatology* 2001; 18(2):123-6.
501. Usonis V, Bakasenas V, Taylor D, Vandepapeliere P. Immunogenicity and reactogenicity of a combined DTPw-hepatitis B vaccine in Lithuanian infants. *European Journal of Pediatrics* 1996; 155(3):189-93.
502. Uter W, Stock C, Pfahlberg A *et al.* Association between infections and signs and symptoms of 'atopic' hypersensitivity - results of a cross-sectional survey among first-year university students in

- Germany and Spain. *Allergy* 2003; 58(7):580-4.
503. Vadheim CM, Greenberg DP, Partridge S, Jing J, Ward JI. Effectiveness and safety of an *Haemophilus influenzae* type b conjugate vaccine (PRP-T) in young infants. Kaiser-UCLA Vaccine Study Group. *Pediatrics* 1993; 92(2):272-9.
 504. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board [see comments]. [Review] [18 refs]. *BMJ* 1997; 314(7086):1033-6.
 505. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. *Journal of Medical Virology*. 67(3):433-439, 2002 Jul.
 506. van de Geijn EJ, Tukkie R, van Philips LA, Punt H. Bilateral optic neuritis with branch retinal artery occlusion associated with vaccination. *Documenta Ophthalmologica* 1994; 86(4):403-8.
 507. van Grunsven PM. The magnitude of fear of adverse effects as a reason for nonparticipation in drug treatment: A short review [Review]. *Journal of Asthma* 2001; 38(2):113-9.
 508. Van Herck K, Van Damme P, Collard F, Thoelen S. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years. *Scandinavian Journal of Gastroenterology* 1999; 34(12):1236-40.
 509. van Steenberghe JE, Baayen D, Peerbooms PGH, Coutinho RA, van den Hoek A. Much gained by integrating contact tracing and vaccination in the hepatitis B antenatal screening program in Amsterdam, 1992-1999. *Journal of Hepatology* 2004; 40(6):979-85.
 510. Vanoli M, Gambini D, Scorza R. A case of Churg-Strauss vasculitis after hepatitis B vaccination [letter]. *Annals of the Rheumatic Diseases* 1998; 57(4):256-7.
 511. Varricchio F, Iskander J, Destefano F *et al.* Understanding vaccine safety information from the vaccine adverse event reporting system [Review]. *Pediatric Infectious Disease Journal* 2004; 23(4):287-94.
 512. Vaudaux B, Steinemann MA. [General hepatitis B vaccination in Switzerland: what is the attitude of vaccinating physicians?]. [German, French]. *Sozial- Und Praventivmedizin* 1998; 43 Suppl 1:S47-56, S121-9.
 513. Vautier G, Carty JE. Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination. *Br J Rheumatol* 1994; 33:991.
 514. Vergne P, Bertin P, Bonnet C, Scotto C, Treves R. Drug-induced rheumatic disorders - Incidence, prevention and management [Review]. *Drug Safety* 2000; 23(4):279-93.
 515. Waisbren BA Sr. Perspectives on hepatitis B vaccination [letter; comment]. *JAMA* 1997; 277(14):1124-5.
 516. Wakeel R, White M. Erythema multiform associated with hepatitis B vaccine. *British Journal of Dermatology* 1992; 126:94-5.
 517. Weintraub Z, Khamaysi N, Elena H, Gershtein V, Orenstein L, Lahat N. Transient surface antigenemia in newborn infants vaccinated with Engerix B: occurrence and duration. *Pediatric Infectious Disease Journal* 1994; 13(10):931-3.
 518. West DJ, Hesley TM, Jonas LC *et al.* Safety and immunogenicity of a bivalent *Haemophilus influenzae* type b/hepatitis B vaccine in healthy infants. Hib-HB Vaccine Study Group. *Pediatric*

- Infectious Disease Journal 1997; 16(6):593-9.
519. WHO. Hepatitis B vaccines: Reported reactions. WHO Drug Inf 1990; 4:129.
 520. Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations [see comments]. JAMA 1997; 278(14):1176-8.
 521. Wolf F, Grezard P, Berard F, Clavel G, Perrot H. Generalized granuloma annulare and hepatitis B vaccination. European Journal of Dermatology 1998; 8(6):435-6.
 522. Xu H, Sun L, Zhou LJ, Fang LJ, Sheng FY, Guo YQ. The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis. Pediatric Nephrology 2003; 18(12):1216-9.
 523. Yamashiki M, Kosaka Y, Nishimura A. An effective intradermal hepatitis B vaccination. Vaccine 1997; 15(15):1618-23.
 524. Yerushalmi B, Raz R, Blondheim O, Shumov E, Koren R, Dagan R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates [published erratum appears in Pediatr Infect Dis J 1997 Nov;16(11):1037]. Pediatric Infectious Disease Journal 1997; 16(6):587-92.
 525. Zaas A, Scheel P, Venbrux A, Hellmann DB. Large artery vasculitis following recombinant hepatitis B vaccination: 2 cases. Journal of Rheumatology 2001; 28(5):1116-20.
 526. Zandman-Goddard G, Shoenfeld Y. SLE and infections [Review]. Clinical Reviews in Allergy & Immunology 2003; 25(1):29-39.
 527. Zavar V, Chuh A. Gianotti-Crosti syndrome in India is not associated with hepatitis B infection. Dermatology 2004; 208(1):87.
 528. Zimmerman RK, Ruben FL, Ahwesh ER. Hepatitis B virus infection, hepatitis B vaccine, and hepatitis B immune globulin [published erratum appears in J Fam Pract 1997 Dec;45(6):464]. [Review] [45 refs]. Journal of Family Practice 1997; 45(4):295-315; quiz 317-8.
 529. Zipp F, Wandinger KP. Recent aspects on the safety of vaccinations in MS [German]. Nervenarzt 2001; 72(10):802-6.
 530. Zipp F, Weil JG, Einhaupl KM. No increase in demyelinating diseases after hepatitis B vaccination [letter]. Nature Medicine 1999; 5(9):964-5.